David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
CALL
Chemours
CC
$2.37B
| $702K | ﹤0.01% |
18,900
-69,400
| -79% | -$2.53M |
|
2777
First Financial Corp
THFF
$940M
| $702K | ﹤0.01% |
+16,722
| New | +$709K |
|
2778
Visteon
VC
$2.77B
| $702K | ﹤0.01% |
10,416
-28,459
| -73% | -$2.14M |
|
2779
Xerox
XRX
$391M
| $701K | ﹤0.01% |
21,912
-1,286,379
| -98% | -$36.3M |
|
2780
eGain
EGAN
$197M
| $696K | ﹤0.01% |
66,589
-7,693
| -10% | -$72.9K |
|
|
ETFC
2781
CALL
DELISTED
E*Trade Financial Corporation
ETFC
| $696K | ﹤0.01% |
15,000
-100
| -0.7% | -$4.76K |
|
2782
Graham Corp
GHM
$1.08B
| $695K | ﹤0.01% |
35,413
+136
| +0.4% | +$3.01K |
|
2783
Freeport-McMoran
FCX
$113B
| $694K | ﹤0.01% |
53,849
-2,724,756
| -98% | -$33M |
|
|
HAYN
2784
DELISTED
Haynes International, Inc.
HAYN
| $694K | ﹤0.01% |
21,148
-21,584
| -51% | -$697K |
|
2785
PUT
Brighthouse Financial
BHF
$3.02B
| $693K | ﹤0.01% |
19,100
-35,400
| -65% | -$1.33M |
|
2786
Camtek
CAMT
$6.69B
| $693K | ﹤0.01% |
77,645
+55,323
| +248% | +$448K |
|
2787
Tredegar Corp
TG
$271M
| $692K | ﹤0.01% |
+42,882
| New | +$726K |
|
2788
RPC Inc
RES
$1.36B
| $690K | ﹤0.01% |
+60,454
| New | +$646K |
|
2789
Frontline
FRO
$9.17B
| $689K | ﹤0.01% |
106,586
+92,711
| +668% | +$551K |
|
|
ABMD
2790
DELISTED
Abiomed Inc
ABMD
| $687K | ﹤0.01% |
2,405
-6,587
| -73% | -$2.19M |
|
2791
PUT
PetMed Express
PETS
$38.8M
| $683K | ﹤0.01% |
30,000
+5,000
| +20% | +$113K |
|
2792
CALL
Rapid7
RPD
$795M
| $683K | ﹤0.01% |
+13,500
| New | +$578K |
|
|
LXFT
2793
DELISTED
Luxoft Holding, Inc.
LXFT
| $683K | ﹤0.01% |
11,641
-27,244
| -70% | -$1.55M |
|
2794
CubeSmart
CUBE
$9.11B
| $682K | ﹤0.01% |
21,292
-385,022
| -95% | -$11.7M |
|
2795
PUT
Asbury Automotive
ABG
$3.77B
| $680K | ﹤0.01% |
9,800
| – | – |
|
2796
CALL
Deutsche Bank
DB
$75.6B
| $680K | ﹤0.01% |
83,800
-65,200
| -44% | -$571K |
|
2797
Scholastic
SCHL
$754M
| $680K | ﹤0.01% |
17,108
+7,126
| +71% | +$294K |
|
|
WDR
2798
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $679K | ﹤0.01% |
+39,269
| New | +$692K |
|
2799
Sonos
SONO
$1.81B
| $678K | ﹤0.01% |
+65,921
| New | +$715K |
|
|
SOHU
2800
Sohu.com
SOHU
$369M
| $677K | ﹤0.01% |
40,826
-16,877
| -29% | -$326K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.